Thermo and Oxford Genetics expand CRISPR toolkits with ERS deals

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/MeletiosVerras)
(Image: Getty/MeletiosVerras)

Related tags: CRISPR, Thermo fisher, Oxford Genetics, ERS Genomics, Broad Institute

Thermo Fisher and Oxford Genetics have announced separate plans to partner with ERS Genomics, gaining access to CRISPR gene editing technology.

Thermo Fisher’s non-exclusive licensing deal with ERS Genomics and the Broad Institute sees it add to its existing CRISPR tools, such as its licensing agreement with ToolGen​.

A spokesperson for Thermo confirmed the tools that the company now as in its portfolio, which includes Invitrogen TrueCut Cas9 Protein v2.0, Invitrogen TrueGuide Synthetic gRNAs and Invitrogen LentiArray CRISPR Libraries.

In addition, Thermo has exclusive rights to the intellectual property of Tal Effector Nuclease (TALEN) technology, which is used in conjunction with CRISPR.

The spokesperson told us that the combination of both technologies provides a complete genome editing toolbox that – in combination with our expertise in gene synthesis – will enable researchers to design, write and edit DNA, biology’s digital code.”

Thermo will also look to further add to its portfolio of genome editing technology, in order to support researchers “develop new drugs and enhance biomanufacturing solutions”​, the spokesperson confirmed.

This nascent area of technology is not the only fast-developing area in which Thermo is consolidating its position, with it also signing a seven-year chimeric antigen receptor (CAR)-T deal to supply Juno Therapeutics technology​ to develop future therapies.

Oxford Genetics aims to meet demand in APAC

Just two days after Thermo completed its deal with ERS Genomics, Oxford Genetics announced that it would also extend its existing non-exclusive license agreement with the patent holder.

The deal sees Oxford Genetics able to supply CRISPR modified cell lines to the Asia Pacific (APAC) region, building upon capabilities within the US and Europe. The agreement means that it will be able to sell its CRISPR tools, reagents and services in the APAC market.

Paul Brooks, chief commercial officer at Oxford Genetics, explained that increased demand is behind the extension of the agreement: “The market for CRISPR tools, reagents and services in the APAC region is forecast to grow in double digits for the next several years as product adoption accelerates while companies explore the full potential of the technology.”

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us


View more